2023-11-13 16:00Financial Performance - The company achieved a total revenue of RMB 537.36 million for the first nine months of 2023, representing a year-on-year growth of 21.7%[3] - The adjusted net profit for the first nine months of 2023, excluding non-cash items, was a loss of RMB 322 million, while the total net profit was a loss of RMB 539 million, narrowing the loss by RMB 304 million compared to the same period last year[3] - The net profit attributable to shareholders for the third quarter was a loss of RMB 108.96 million, with a basic and diluted earnings per share of -0.06 yuan[5] - The company reported a net loss of ¥4,979,423,376.98 for the first three quarters of 2023, compared to a net loss of ¥4,448,257,868.41 in the same period of 2022[17] - The company's net profit for the first three quarters of 2023 was -539,287,265.88 RMB, compared to -842,652,515.00 RMB in the same period of 2022, showing an improvement of approximately 36%[19] - The company's total comprehensive income for the first three quarters of 2023 was -337,601,250.11 RMB, compared to -279,487,002.07 RMB in 2022[20] - The basic earnings per share for 2023 was -0.31 RMB, an improvement from -0.59 RMB in 2022[20] - The operating profit for the first three quarters of 2023 was -548,854,514.11 RMB, an improvement from -842,055,946.80 RMB in 2022, indicating a recovery trend[19] Cash Flow and Assets - As of September 30, 2023, the company held cash and cash equivalents of approximately RMB 8.58 billion, ensuring sufficient cash flow for ongoing projects[4] - Cash and cash equivalents were reported at ¥8,261,546,048.38, down from ¥8,742,914,140.21 at the end of 2022[16] - The total current assets amounted to ¥8,945,496,793.93, a decrease from ¥9,299,708,518.08 at the end of 2022[16] - The total assets of the company as of the end of the reporting period were RMB 10.04 billion, a decrease of 2.80% compared to the previous year[6] - The total assets as of September 30, 2023, were ¥10,039,622,087.37, compared to ¥10,328,783,979.11 at the end of 2022[17] - The total liabilities as of September 30, 2023, were ¥2,659,650,754.08, slightly down from ¥2,684,457,313.64 at the end of 2022[17] - The company’s cash and cash equivalents at the end of the period increased to 5,440,243,367.28 RMB from 4,414,372,466.48 RMB in the previous year, marking a growth of approximately 23.2%[22] Research and Development - The company's R&D expenditure for the third quarter was RMB 188.52 million, accounting for 117.97% of the revenue, an increase of 17.26 percentage points year-on-year[5] - Research and development expenses increased to 549,716,988.65 RMB in 2023 from 475,344,994.01 RMB in 2022, reflecting a growth of about 15.6%[19] - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[15] Shareholder Information - The number of common shareholders at the end of the reporting period was 20,286[11] - The largest shareholder, HKSCC NOMINEES LIMITED, holds 728,962,157 shares, representing 41.32% of total shares[11] Revenue Sources - The sales growth of the drug Oubatinib (Yinokai®) significantly contributed to the revenue increase since its inclusion in the new medical insurance catalog[3] - Total revenue for the first three quarters of 2023 reached ¥537,361,649.40, an increase of 21.7% compared to ¥441,612,184.36 in the same period of 2022[18] - Total operating costs for the first three quarters of 2023 were ¥1,088,452,691.35, down 16.4% from ¥1,301,756,168.51 in the previous year[18] - The company reported government subsidies of RMB 4.98 million for the third quarter, contributing to its financial performance[7] - The company’s sales revenue from goods and services received cash of 552,799,573.58 RMB in 2023, up from 389,838,923.35 RMB in 2022, representing a growth of about 41.8%[21]